Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil

Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil

Author Freitas, Carolina Gomes Autor UNIFESP Google Scholar
Walsh, Michael Google Scholar
Atallah, Alvaro Nagib Autor UNIFESP Google Scholar
Abstract Background: Warfarin is a commonly used anticoagulant. Whether a given dose of the different formulations of Brazilian warfarin will result in the same effect on the international normalized ratio (INR) is uncertain. The aim of the WARFA trial is to determine whether the branded and two generic warfarins available in Brazil differ in their effect on the INR. Methods: WARFA is a cross-over RCT comparing three warfarins. The formulations tested are the branded Marevan (R) (Uniao Quimica/Farmoquimica) and two generic warfarin (manufactured respectively by Uniao Quimica Farmaceutica Nacional and Laboratorio Teuto Brasileiro). All of them were manufactured in Brazil, are available in all settings of the Brazilian healthcare system and were purchased from retail drugstores. Eligible participants had atrial fibrillation or flutter, had been using warfarin for at least 2 months with a therapeutic range of 2.0-3.0 and had low variability in INR results during the 1st period of the trial. Our primary outcome, for which we have an equality hypothesis, is the difference between warfarins in the mean absolute difference between two INR results, obtained after three and 4 weeks with each drug. Our secondary outcomes, that will be tested for inequality (except for the mean INR, which will be tested for equality), include the difference in the warfarin dose, and time in therapeutic range. Clinical events and adherence were also recorded and will be reported. Discussion: To our knowledge, WARFA will be the first comparison of the more readily applicable INR results between branded and generic warfarins in Brazil. WARFA is important because warfarins are commonly switched between in the course of a chronic treatment in Brazil. Final results of WARFA are expected in May 2017. Trial registration: ClinicalTrials.gov NCT02017197. Registered 11 December 2013.
Keywords Warfarin
Generic drug
Generic drugs
Brazil
Statistical analysis plan
Crossover
Randomized crossover trial
Randomized controlled trial crossover design
Therapeutic equivalence
Atrial fibrillation
xmlui.dri2xhtml.METS-1.0.item-coverage London
Language English
Sponsor Sao Paulo Research Foundation FAPESP)
CAPES
Brazilian Government Foundation for Higher Education (CGF)
Federal University of Sao Paulo (ANA)
New Investigator's Award - Canadian Institutes of Health Research (MW)
Cardiac Electrophysiology Department at the Federal University of Sao Paulo
Grant number FAPESP: 2013/22618-6
CAPES
Brazilian Government Foundation for Higher Education (CGF)
Federal University of Sao Paulo (ANA)
New Investigator's Award - Canadian Institutes of Health Research (MW)
Cardiac Electrophysiology Department at the Federal University of Sao Paulo
Date 2017
Published in Bmc Cardiovascular Disorders. London, v. 17, p. -, 2017.
ISSN 1471-2261 (Sherpa/Romeo, impact factor)
Publisher Biomed Central Ltd
Extent -
Origin http://dx.doi.org/10.1186/s12872-017-0584-4
Access rights ACESSO ABERTO
Type Article
Web of Science ID WOS:000403050900002
URI https://repositorio.unifesp.br/handle/11600/53666

Show full item record




File

Name: WOS000403050900002.pdf
Size: 395.4Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account